According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to ...

Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial. It’s been a big week for this class of ...

Eli Lilly is one of the companies developing monoclonal antibody therapies for COVID-19. The company’s bamlanivimab received an Emergency Use Authorization (EUA) in mid-November. The company has ...

Photographer: Michael Nagle (Bloomberg) -- Eli Lilly & Co.’s antibody therapy reduced nursing home residents’ risk of symptomatic Covid-19 by as much as 80% when used preventively in a study.

The results are in from the first monoclonal antibody drug for COVID-19 tested ... in patients with mild-to-moderate COVID-19 symptoms compared to control patients. The drug’s manufacturer, Eli Lilly, ...

Photographer T. Narayan/Bloomberg Photographer: T. Narayan/Bloomberg (Bloomberg) -- Eli Lilly and Co.’s combination antibody drug for Covid-19 outperformed one of its components that’s now ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

such as the November 2020 partnership with Junshi Biosciences for developing COVID-19 antibody therapies, reinforcing investor confidence in future growth prospects. Additionally, Eli Lilly’s ...